BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
323 results:

  • 1. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. DNA methylation regulator-based molecular subtyping and tumor microenvironment characterization in hepatocellular carcinoma.
    Zhao J; Liu Z; Yang K; Shen S; Peng J
    Front Immunol; 2024; 15():1333923. PubMed ID: 38736884
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification of vitamin D-related signature for predicting the clinical outcome and immunotherapy response in hepatocellular carcinoma.
    Wang T; Han L; Xu J; Guo B
    Medicine (Baltimore); 2024 May; 103(19):e37998. PubMed ID: 38728505
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and pd-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
    World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Predicting effect of anti-pd-1/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
    Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
    Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and pd-1 inhibitors.
    Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
    Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
    Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
    Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Anti-pd-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
    Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
    BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunity.
    Wang X; Niu R; Yang H; Lin Y; Hou H; Yang H
    Cell Biol Int; 2024 May; 48(5):577-593. PubMed ID: 38501437
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. New advances in the study of pd-1/PD-L1 inhibitors-induced liver injury.
    Yue M; Li C; Li G
    Int Immunopharmacol; 2024 Apr; 131():111799. PubMed ID: 38460297
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma.
    Liang Y; Zhong D; Zhang Z; Su Y; Yan S; Lai C; Yao Y; Shi Y; Huang X; Shang J
    BMC Cancer; 2024 Mar; 24(1):291. PubMed ID: 38438842
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-pd1 therapy.
    Li ZC; Wang J; Liu HB; Zheng YM; Huang JH; Cai JB; Zhang L; Liu X; Du L; Yang XT; Chai XQ; Jiang YH; Ren ZG; Zhou J; Fan J; Yu DC; Sun HC; Huang C; Liu F
    Cell Rep; 2024 Mar; 43(3):113877. PubMed ID: 38421869
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without pd-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.
    Wang H; Huang H; Liu T; Chen Y; Li J; He M; Peng J; Liang E; Li J; Liu W
    Front Immunol; 2024; 15():1325330. PubMed ID: 38404585
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Interferon-α induces differentiation of cancer stem cells and immunosuppression in hepatocellular carcinoma by upregulating CXCL8 secretion.
    Ma YT; Zheng L; Zhao CW; Zhang Y; Xu XW; Wang XY; Niu GP; Man ZS; Gu F; Chen YQ
    Cytokine; 2024 May; 177():156555. PubMed ID: 38387232
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
    Ma YN; Jiang X; Song P; Tang W
    Biosci Trends; 2024 Mar; 18(1):21-41. PubMed ID: 38382930
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma.
    Men B; Cui H; Han Z; Jin X; Xu Q; Jin Y; Piao Z; Zhang S
    Front Immunol; 2024; 15():1337396. PubMed ID: 38380330
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Characterization of lymphocyte-rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures.
    Ahn B; Ahn HS; Shin J; Jun E; Koh EY; Ryu YM; Kim SY; Sung CO; Shim JH; Hong J; Kim K; Kang HJ
    Liver Int; 2024 May; 44(5):1202-1218. PubMed ID: 38363048
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
    Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
    Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-pd-1 Antibody: A Multicenter Retrospective Study.
    Wu JY; Wu JY; Fu YK; Ou XY; Li SQ; Zhang ZB; Zhou JY; Li B; Wang SJ; Chen YF; Yan ML
    Ann Surg Oncol; 2024 May; 31(5):3073-3083. PubMed ID: 38316732
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 17.